Please login to the form below

Not currently logged in
Email:
Password:

Hikma appoints group scientific officer and global head of R&D

Dr Surendera Tyagi joins the pharma group from Fresenius Kabi

Speciality pharmaceutical group Hikma has appointed a group scientific officer and gloval head of R&D in the form of Dr Surendera Tyagi, who will focus on the group’s non-injectables business and will become a member of Hikma’s executive committee.

He joins the pharma group from Fresenius Kabi, where he most recently led its US innovation and development centre.

Prior to this, he served as chief scientific officer for Sabur Pharma, an oncology company that was acquired by Fresenius in 2008.

Tyagi has also held various scientific and regulatory roles at Roche IGEN, Abbott/Hospita and Scwarz Pharma.

He said: “Hikma’s track record of delivering affordable, quality medicines to people who need them is a purpose that I share, and I look forward to accelerating their R&D efforts by advancing and expanding their pipeline.”

22nd January 2018

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Onyx Health Ltd

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Latest intelligence

Pandemic preparedness
The pandemic preparedness paradox
Why our efficient ‘just in time’ mentality must be replaced with a resilient ‘just in case’ activity...
Emre Vural
Sourcing R&D innovation: why pharma companies need to evolve their business models
Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?
2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...

Infographics